VRNS earnings approach with shorts retreating and options tilted bullish

Six days before Varonis reports, VRNS is up 5% over the past week while its closest peers fell a median 2.7%. The positioning data and the analyst community are pointing in opposite directions, and that gap narrows on 26 October.

Analysts reset, options disagree

Barclays became the latest firm to cut VRNS, with Saket Kalia downgrading to Equal-Weight on 19 October. He joins a roster that includes Jefferies, TD Cowen, Wells Fargo, DA Davidson, RBC Capital, Piper Sandler, and Rosenblatt, all of which moved to neutral last Thursday. Consensus now sits at Hold with a mean price target of $51.07, roughly 4.8% above the current $48.70.

The common thread across the downgrades is the reported Proofpoint acquisition talks. Analysts flagged that the news hit during the final weeks of the September quarter, when a large share of deals was still open. Two firms moved the other way: Citigroup raised its target to $49.75 and Baird lifted to $50, both holding Neutral.

Options traders are reading the situation differently. The put-call ratio stands at 0.46, more than two standard deviations below its 20-day mean of 0.57. That is the most call-heavy positioning the options market has shown in weeks, running against the analyst caution.

Short sellers have already voted

Short interest fell to 5.2% of free float as of 19 October, down roughly 20% from the prior week and down more than 23% over the past month. That is a sustained retreat, not a one-session move.

The lending market remains loose. Availability sits at 2,692%, meaning there are approximately 27 shares available to borrow for every one currently lent out. Cost to borrow rose 72% over the past week to 0.43%, but from a low base. The borrow market is not tight. The cost move reflects the mechanics of a shrinking short book rather than any scarcity of supply.

The ORTEX short score is 38.9, down from 44.5 two weeks ago. The step down tracks the pace of covering.

Retail attention and the index backdrop

ORTEX Alt Data shows retail attention at 3.6 standard deviations above its own 90-day average, measured via Wikipedia views and ORTEX page traffic as of 17 October. The data captures attention, not a revenue or earnings signal.

One structural fact is worth noting for longer-term holders. ORTEX forecasts an 84% probability that VRNS is deleted from the Russell 2000 and Russell 3000, tied to the reported Proofpoint cash acquisition. The estimated trade date is 29 June 2027. That is a forecast, not a confirmed index event. The disclosure applies: these are probabilities, not announcements.

• Short interest: 5.2% of free float, down 23% in one month
• Availability: 2,692%, loose borrow market
• Cost to borrow: 0.43%, up 72% over the past week
• Options PCR: 0.46, z-score of -2.1 against the 20-day mean
• Analyst consensus: Hold, mean target $51.07
• ORTEX short score: 38.9, down from 44.5 two weeks ago
• Next earnings: 26 October